We conceive, create and internally develop blood tests that detect your body's response to disease in the earliest possible stages. For us, this is about unlocking the quality-of-life preservation that exists at stage zero. This is a different endpoint in early detection. And when you change the endpoint, everything changes. 

Model.

Our model is characterized by speed, efficiency and risk mitigation. You don’t hear these words in healthcare very often. But that doesn’t make it right. So, we’ve made them central to our business.

Process.

Our process is driven by data and led by technology, with AI woven into every stage of the diagnostic development journey. Tech has redefined nearly every product and service in every industry except healthcare. Until now.

Product design.

Our products are designed to seamlessly integrate within existing care pathways, with clearly defined improvements to physical, mental, emotional and financial health outcomes. We will only take on projects where we can create value for patients, providers and payers.

Commercial focus.

Our commercial focus priortizes abundance over scarcity, with a clear recognition that maximizing social impact can actually maximize financial results. We live in a world where profit and purpose no longer have to be mutually exclusive. Which is why we are committed to bringing precision health solutions to the masses. Cancer doesn’t discriminate, so neither do we.

Since our founding, we've strived for better science. We've strived for better data. We've strived for better everything.

Better science.

Waiting for cancer to live, grow, die and shed into the bloodstream never made a lot of sense to us when it comes to detecting cancer early. Yet, 94% of scientific papers in liquid biopsy reference some form of tumor- derived genetic material in their research. While everyone else was trying to detect cancer, we took the road less traveled — investing in the dynamic genomic response of the patient, through changes in RNA gene expression. And it worked.

Better data

While everyone else worked for incremental improvement over zero, we worked backward from one hundred. For us, every percentage point short of perfection represents your life. Someone in your family’s life. Someone in our family’s life.

Better everything.

While everyone else succumbed to catching lightning in a bottle, we developed a disease-agnostic platform that systematically stacks the odds in favor of breakthroughs.

We are better for this.

And so are patients.